Dihexa is the most potent nootropic compound most people have never heard of. It activates the HGF (hepatocyte growth factor)/c-Met signaling pathway, which drives synaptogenesis, the formation of new neural connections. In vitro, it was shown to be 10 million times more potent than BDNF at promoting new connections. Rat studies showed improved spatial learning and memory. The problem: zero human trials, and c-Met is a proto-oncogene. Activating it could theoretically promote tumor growth. The community uses it anyway, typically in short cycles with careful monitoring.
Dihexa Protocol
Dose: 10-20mg oral or SubQ | Frequency: Once daily | Cycle: 2-4 weeks on, 4+ weeks off. Short cycles due to c-Met cancer concerns. | Route: Oral (sublingual), SubQ
Reconstitution: Often taken orally (sublingual or capsule). For SubQ: 1mL bacteriostatic water per vial, calculate based on mg content.. Free reconstitution calculator.
The c-Met pathway is a proto-oncogene. This is the main safety concern. Short cycles only. Monitor for any unusual lumps or growths. Get regular check-ups. This is not a casual daily supplement.
Dihexa Effects
Cognitive enhancement (60%). Improved memory, learning, and verbal fluency reported by users. No human trial data.
Synaptogenesis (50%). The HGF/c-Met pathway drives new synapse formation. The mechanism is well-characterized in vitro.
Neuroprotection (40%). Potential neuroprotective effects through HGF pathway. Investigated for Alzheimer's in preclinical models.
Dihexa Side Effects
Headache (10%). Mild headache reported by some users. Usually transient.
Theoretical cancer risk (0%). c-Met is a proto-oncogene. Activating it could theoretically promote tumor growth. This has not been observed in animal studies at standard doses, but no long-term safety data exists.
Dihexa Dosing by Use Case
Condition
Dose
Duration
Notes
Cognitive enhancement
10-20mg oral or SubQ daily
2-4 weeks, then at least 4 weeks off
The primary use case. Users report improved memory, verbal fluency, and learning speed. The effects are subtle but accumulate over the cycle. Short cycles are strongly recommended due to c-Met concerns.
Neuroprotection (experimental)
10mg daily
2 weeks
Investigated in preclinical Alzheimer's models. HGF promotes neuronal survival and synapse repair. Entirely experimental. No human data for neuroprotective use.
Dihexa Results Timeline
Day 1-7, Subtle shifts: Some users notice improved verbal recall and mental clarity within the first week. Others feel nothing until week 2.
Week 2-4, Peak cognitive effects: Memory and learning improvements become more noticeable. Verbal fluency improves. This is the end of a recommended cycle. Stop here.
Frequently Asked Questions About Dihexa
What is dihexa?
Dihexa is a small peptide analog of angiotensin IV that activates the HGF (hepatocyte growth factor)/c-Met signaling pathway. This pathway drives synaptogenesis (new neural connections) and neuronal survival. In vitro, dihexa was shown to be approximately 10 million times more potent than BDNF at promoting new synapse connections. It was developed at Washington State University. Zero human clinical trials exist.
Is dihexa safe?
Unknown. The main concern is the c-Met pathway, which is a proto-oncogene. c-Met activation promotes cell growth and survival, which is beneficial for neurons but could theoretically promote tumor growth in other tissues. No human safety data exists. The community uses short cycles (2-4 weeks) with long breaks to limit exposure. This is the highest-risk compound on this wiki by evidence profile.
What is the best dihexa dosage?
10-20mg daily, oral (sublingual) or subcutaneous. Start at 10mg. Most community protocols run 2-4 weeks maximum. No human dosing studies exist. These numbers come from community consensus and animal study extrapolation.
How do you take dihexa?
Most people take it sublingually (under the tongue) or in oral capsules. SubQ injection is an alternative. Sublingual may have better bioavailability than swallowed capsules. Some research suppliers sell it as a liquid for sublingual use.
Evidence
Early research. Dihexa is an angiotensin IV analog that activates the HGF/c-Met pathway. A single study showed it was 10 million times more potent than BDNF at promoting new synapse connections in vitro. Rat studies showed improved cognition. Zero human trials. The potency claim is real but in vitro, and the cancer risk from c-Met activation is a legitimate concern.
Approval status: Not approved. Preclinical only.
References
Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther, 2014. PMID 24860065
McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther, 2013. PMID 23370794
Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis, 2015. PMID 25633678
Storage
Lyophilized: Refrigerate or freeze. Keep dry and protected from light.
Reconstituted: Refrigerate. Use within 2-4 weeks.
Water: Bacteriostatic water if using SubQ. Oral formulations are pre-made.
Needle: 30-31 gauge, 0.5 inch for SubQ if not using oral route
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
This page is a community reference, not medical advice. Content reflects what users report, not clinical recommendations. Nothing here is approved for human use unless specifically noted. Always consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
